Transdermal Tizanidine Patch for Spasticity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oral administration of tizanidine leads to significant fluctuations in blood serum concentration, causing side effects such as somnolence and dizziness due to its short half-life and frequent dosing, which interferes with everyday activities and poses risks related to alertness tasks.
Innovation Solution
A transdermal patch preparation delivering a modified release form of tizanidine or its pharmaceutically acceptable salt, providing continuous drug delivery for at least 24 hours with enhanced bioavailability and reduced absorption variability, utilizing a patch composition that includes tizanidine hydrochloride, sorbate components, and other additives to improve skin permeation and minimize side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral administration of tizanidine is used, then therapeutic effect for spasticity is achieved, but significant fluctuations in blood serum concentration occur causing side effects such as somnolence and dizziness
Solution Approach 1:
The patent changes the administration route from oral to transdermal, fundamentally altering the pharmacokinetic parameters of tizanidine delivery. This transition eliminates first-pass metabolism and achieves more stable plasma concentration profiles, directly resolving the contradiction between therapeutic efficacy and side effect reduction
Solution Approach 2:
The transdermal patch provides continuous drug delivery through the skin, maintaining steady plasma concentrations of tizanidine over extended periods. This continuous action prevents the peaks and troughs associated with oral dosing, thereby reducing side effects while sustaining therapeutic benefit
2Duration of action of moving object
If oral administration with frequent dosing is used, then therapeutic coverage is maintained, but alertness is impaired interfering with everyday activities
Solution Approach 1:
The transdermal patch delivers tizanidine continuously through the skin, maintaining therapeutic coverage without requiring frequent dosing interruptions. This continuous delivery sustains plasma concentrations within the therapeutic window while avoiding the alertness impairment associated with repeated oral dosing
3Object-affected harmful factors
If transdermal patch preparation is used, then side effects are reduced and bioavailability is improved, but new formulation complexity is introduced
Solution Approach 1:
The transdermal patch employs composite material structures including adhesive layers, drug reservoirs, and protective membranes to achieve controlled transdermal delivery of tizanidine. While this introduces formulation complexity, it successfully reduces side effects and improves bioavailability through sustained release mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The transdermal patch significantly reduces side effects like somnolence and dizziness, maintaining therapeutic efficacy for spasticity management with improved bioavailability and prolonged drug delivery, offering a more stable plasma concentration profile compared to oral administration.
Implementation Method 1
transdermal administration of the drug... excellent skin permeation rate of the drug
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
An object of the present invention is to provide a method for the treatment of a patient suffering from spasticity comprising administering to said patient a modified release dosage form comprising tizanidine or a pharmaceutically acceptable salt thereof. The present invention relates to a method of administering a transdermal patch preparation comprising tizanidine or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the transdermal patch preparation releases about 4 mg to about 36 mg of tizanidine or a pharmaceutically acceptable salt thereof for at least about 24 hours.